SARS-CoV-2 N protein IgG antibody detection employing nanoporous anodized alumina: A rapid and selective alternative for identifying naturally infected individuals in populations vaccinated with spike protein (S)-based vaccines
Methods to detect naturally infected individuals, especially during or after a pandemic, are valuable in populations with a high rate of vaccination. Having in mind that after the COVID-19 pandemic people has been vaccinated against the virus by Spike protein (S)-based vaccines, we present in this p...
Gespeichert in:
Veröffentlicht in: | Sensors and actuators. B, Chemical Chemical, 2024-11, Vol.419, p.136378, Article 136378 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Methods to detect naturally infected individuals, especially during or after a pandemic, are valuable in populations with a high rate of vaccination. Having in mind that after the COVID-19 pandemic people has been vaccinated against the virus by Spike protein (S)-based vaccines, we present in this paper a novel nanosensor based on gated nanoporous anodic alumina (NAA) material to detect naturally infected individuals in populations with high rates of vaccination. The nanosensor developed is based on a protein-capped nanomaterial for the identification of IgG antibodies that can detect nucleocapsid protein (N) of SARS-CoV-2. The NAA material has been loaded with an indicator (Rhodamine B (RhB)) and the pores of the material have been blocked with SARS-CoV-2 nucleocapsid protein (N) attached to a specific aptamer. In presence of antibodies against this antigen, the pores are uncapped, triggering the dye release and a fluorescent signal as a result. The biosensor has been tested in vitro and simulated serum for IgG detection, proving a detection limit of 1 µg/mL. Moreover, specificity assays with N proteins from other coronaviruses have proved the robustness and efficacy of this nanosensor. Finally, the system has been tested on samples from patients that contained SARS-CoV-2 antibodies, demonstrating its potential for the discrimination of individuals that have been vaccinated or infected by SARS-CoV-2 virus.
•Rapid and accurate tests for antibody detection of SARS-CoV-2 is crucial for disease control and management of this virus.•We present a nanosensor based on protein-capped nanomaterial to detect antibodies against nucleocapsid protein of SARS-CoV-2.•The biosensor is tested in vitro, for IgG detection, proving a Limit of Detection (LOD) of 1 µg/mL and in clinical samples.•The system shows high selectivity for antibodies resistant to SARS-CoV-2 N protein. |
---|---|
ISSN: | 0925-4005 |
DOI: | 10.1016/j.snb.2024.136378 |